A detailed history of Zimmer Partners, LP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Zimmer Partners, LP holds 33,650 shares of BPMC stock, worth $3.11 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
33,650
Previous 21,100 59.48%
Holding current value
$3.11 Million
Previous $1.95 Million 50.46%
% of portfolio
0.05%
Previous 0.04%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$82.48 - $101.39 $1.04 Million - $1.27 Million
12,550 Added 59.48%
33,650 $2.93 Million
Q3 2024

Nov 14, 2024

BUY
$84.1 - $120.5 $1.77 Million - $2.54 Million
21,100 New
21,100 $1.95 Million
Q2 2023

Aug 14, 2023

BUY
$42.2 - $66.37 $1.2 Million - $1.88 Million
28,400 New
28,400 $1.79 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.52B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Zimmer Partners, LP Portfolio

Follow Zimmer Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zimmer Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Zimmer Partners, LP with notifications on news.